Despite recommendations from the American College of Rheumatology (ACR) and other international societies, the use of treat‐to‐target strategies with urate‐lowering therapy (ULT) has not increased over the past 20 years. To encourage more adherence to ULT for treating patients with gout, the ACR updated its guidelines to provide stronger evidence in favor of ULT as the preferred therapeutic agent. Which of the following agents does the ACR recommend for first-line therapy for patients with gout?
Better luck next time
Nice job!
Rheumatology and Arthritis Learning Network® is an online resource for the latest developments in rheumatology practice, providing a customized experience for readers to stay informed about the topics that matter most to them.
Upadacitinib Shows Positive Results in Clinical Trials for AS, nr-axSpA
Late-Breaking Results from Phase 3 Trials of Risankizumab